Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Mini oral session 1 - Gastrointestinal tumours, upper digestive

LBA79 - GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

Date

21 Oct 2023

Session

Mini oral session 1 - Gastrointestinal tumours, upper digestive

Topics

Tumour Site

Gastric Cancer;  Gastro-Oesophageal Junction Cancer

Presenters

Xiaotian Zhang

Citation

Annals of Oncology (2023) 34 (suppl_2): S1254-S1335. 10.1016/S0923-7534(23)04149-2

Authors

X. Zhang1, J. Wang2, G. WANG3, Y. Zhang4, Q. Fan5, L. Chuangxin6, C. Hu7, M.L. Sun8, Y. Wan9, S. Sun10, J. Wang11, L. Zhang12, Y. Shu13, J. Luo14, D. Zhu14, H. Wang14, Y. Xu14, Q. Shi14, J.J. Yang15, L. Shen1

Author affiliations

  • 1 Department Of Gastrointestinal Medical Oncology, Beijing Cancer Hospital, 100142 - Beijing/CN
  • 2 Gastroenterology Department, Henan Cancer Hospital, 450008 - Zhengzhou/CN
  • 3 Cancer Chemotherapy Department, Anhui Provincial Hospital, 230001 - Hefei/CN
  • 4 Department Of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, 150084 - Harbin/CN
  • 5 Oncology Department, The First Affiliated Hospital of Zhengzhou University, 450052 - Zhengzhou/CN
  • 6 Medical Oncology Department, Henan Provincial People's Hospital, 450003 - Zhengzhou/CN
  • 7 Medical Oncology Department, Anhui Provincial Cancer Hospital, 230031 - Hefei/CN
  • 8 Oncology Department, Jinan Central Hospital, 250013 - Jinan/CN
  • 9 Department Of Gastroenterology And Medical Oncology, Jiangxi Cancer Hospital, Nanchang/CN
  • 10 Oncology Department, Xuzhou Central Hospital, 221009 - Xuzhou/CN
  • 11 Oncology Department, Affiliated Hospital of Jining Medical University, 272129 - Jining/CN
  • 12 Oncology, Chongqing University Three Gorges Hospital, Chongqing/CN
  • 13 Oncology Department, Jiangsu Province Hospital, 210029 - Nanjing/CN
  • 14 Clinical Development, CStone Pharmaceuticals Co. Ltd., 200126 - Shanghai/CN
  • 15 Clinical Development, CStone Pharmaceuticals Co. Ltd., 201203 - Shanghai/CN

Resources

This content is available to ESMO members and event participants.
Login

Abstract LBA79

Background

GEMSTONE-303 is a randomized, double-blinded, multi-center phase 3 trial evaluating sugemalimab (suge), a full-length, fully human anti-PD-L1 mAb + CAPOX vs placebo + CAPOX as the first-line treatment for patients (pts) with advanced G/GEJ adenocarcinoma. It is the first reported phase 3 trial of an anti-PD-L1 mAb in this disease that met the dual primary endpoints of PFS and OS. Here, we report the final analysis results of dual primary endpoints.

Methods

Eligible pts with previously untreated, no known HER2-positive status, PD-L1 expression ≥5%, unresectable advanced or metastatic G/GEJ adenocarcinoma were randomized 1:1 to receive suge/placebo (1200 mg, Q3W, IV) + CAPOX (capecitabine, 1000 mg/m2, PO, BID, D1-14, Q3W; oxaliplatin, 130 mg/m2, IV, Q3W; max 6 cycles). Stratification factors were ECOG PS (0 or 1) and PD-L1 expression levels (5-9% or ≥10%). Primary endpoints were PFS and OS. Data cutoff dates of the preplanned PFS and OS final analyses were 6 Aug 2022 and 9 Jul 2023, respectively.

Results

A total of 479 pts were randomized to suge+CAPOX (N=241) and placebo+CAPOX (N=238) arms between 9 Apr 2019 and 29 Dec 2021. The PFS and OS final analysis showed a significant improvement of the dual primary endpoints with suge+CAPOX vs placebo+CAPOX. The ORR was 68.6% with suge+CAPOX and 52.7% with placebo+CAPOX. The OS benefits were observed across all subgroups. The incidences of G3-5 suge/placebo-related AEs were 31.1% in suge+CAPOX arm and 28.7% in placebo+CAPOX arm. No new safety signals were observed. Table: LBA79

PD-L1 Expression Level >=5% Suge+CAPOX Placebo+CAPOX
N=241 N=238
PFS (Months)
Median (95% CI) 7.62 (6.37, 7.89) 6.08 (5.06, 6.44)
P-value <0.0001
HR (95% CI) 0.66 (0.54, 0.81)
OS (Months)
Median (95% CI) 15.64 (13.27, 17.81) 12.65 (10.64, 14.06)
P-value 0.0060
HR (95% CI) 0.75 (0.61, 0.92)
OS Rate
12 Months (95% CI) 61.25% (54.77%, 67.08%) 52.02% (45.44%, 58.18%)
24 Months (95% CI) 29.90% (23.79%, 36.23%) 23.28% (17.81%, 29.18%)
PD-L1 Expression Level >=10% N=130 N=128
PFS (Months)
Median (95% CI) 7.79 (6.77, 9.99) 5.52 (4.83, 6.67)
P-value 0.0001
HR (95% CI) 0.58 (0.43, 0.77)
OS (Months)
Median (95% CI) 17.81 (14.36, 21.16) 12.45 (9.89, 13.86)
P-value 0.0022
HR (95% CI) 0.64 (0.48, 0.85)

Conclusions

Sugemalimab in combination with CAPOX demonstrates statistically significant and clinically meaningful improvements in PFS and OS, with a manageable safety profile. These findings support suge+CAPOX as new first-line treatment option for pts with PD-L1 expression ≥5%, advanced G/GEJ adenocarcinoma.

Clinical trial identification

NCT03802591.

Editorial acknowledgement

Medical writing and editorial assistance were provided by Mengxin Chen from CStone Pharmaceuticals, funded by the study sponsor.

Legal entity responsible for the study

CStone Pharmaceuticals.

Funding

CStone pharmaceuticals.

Disclosure

J. Luo: Financial Interests, Personal, Full or part-time Employment: CStone Pharmaceuticals (Su Zhou) Co., Ltd.; Financial Interests, Personal, Stocks/Shares: CStone Pharmaceuticals (Su Zhou) Co., Ltd.. D. Zhu: Financial Interests, Personal, Stocks/Shares: CStone Pharmaceuticals (Su Zhou) Co., Ltd.; Financial Interests, Personal, Full or part-time Employment: CStone Pharmaceuticals (Su Zhou) Co., Ltd.. H. Wang: Financial Interests, Personal, Full or part-time Employment: CStone Pharmaceuticals (Su Zhou) Co., Ltd.. Y. Xu: Financial Interests, Personal, Full or part-time Employment: CStone Pharmaceuticals (Su Zhou) Co., Ltd.. Q. Shi: Financial Interests, Personal, Stocks/Shares: CStone Pharmaceuticals (Su Zhou) Co., Ltd.; Financial Interests, Personal, Full or part-time Employment: CStone Pharmaceuticals (Su Zhou) Co., Ltd.. J.J. Yang: Financial Interests, Personal, Full or part-time Employment: CStone Pharmaceuticals (Su Zhou) Co., Ltd.; Financial Interests, Personal, Stocks/Shares, CStone Pharmaceuticals (Su Zhou) Co., Ltd.: CStone Pharmaceuticals (Su Zhou) Co., Ltd.; Financial Interests, Personal, Member of Board of Directors: CStone Pharmaceuticals (Su Zhou) Co., Ltd.. L. Shen: Financial Interests, Personal, Other, Consulting fees: Mingji biopharmaceutical, Haichuang pharmaceutical, Herbour biomed; Financial Interests, Personal, Advisory Board: MSD, Merck, BMS, BI, Sanofi, Roche, SERVIER, AZ; Financial Interests, Institutional, Funding: Beijing Xiantong Biomedical Technology, Qilu Pharmaceutical, ZaiLab Pharmaceutical (Shanghai), Alphamab Oncology, Yaojie Ankang (Nanjing) Technology Co., Ltd., BeiGene, Ltd., Qiyu Biotechnology (Shanghai) Co., Ltd., BriSTAR immunotech; Financial Interests, Institutional, Local PI: Merck Healthcare KGaA, Roche; Financial Interests, Institutional, Trial Chair: Rongchang Pharmaceutical, Innovent, BeiGene, Ltd., Qilu Pharmaceutical, NovaRock Biotherapeutics Limited. All other authors have declared no conflicts of interest.

Resources from the same session

Invited Discussant LBA78 and 1512MO

Presenter: Hanneke van Laarhoven

Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.